Illumina HiSeq 2000 sequencing; ChIP-seq against the CTCF protein in Raji cells with inducible BZLF1 protein (KF717093.1) prior to and post induction of BZLF1.
Sample information curated by ChIP-Atlas
Antigen
Antigen Class
No description
Antigen
NA
Cell type
Cell type Class
Blood
Cell type
RAJI
Primary Tissue
Blood
Tissue Diagnosis
Malignant Lymphoma - Burkitts Type
Attributes by original data submitter
Sample
ENA first public
2019-04-01
ENA last update
2019-03-18
ENA-CHECKLIST
ERC000011
External Id
SAMEA5425651
INSDC center alias
Research Unit Gene Vectors Helmholtz Zentrum Munchen German Research Center for Environmental Health and German Center for Infection Research (DZIF), Partner site Munich, Germany
INSDC center name
Research Unit Gene Vectors Helmholtz Zentrum Munchen German Research Center for Environmental Health and German Center for Infection Research (DZIF), Partner site Munich, Germany
INSDC first public
2019-04-01T17:02:00Z
INSDC last update
2019-03-18T13:16:45Z
INSDC status
public
Submitter Id
E-MTAB-7787:Raji iBZLF1 4816 ChIP 0 h
broker name
ArrayExpress
cell line
Raji
cell type
B-lymphoblast
common name
human
sample name
E-MTAB-7787:Raji iBZLF1 4816 ChIP 0 h
Sequenced DNA Library
library_name
Raji iBZLF1 4816 ChIP 0 h_s
library_strategy
ChIP-Seq
library_source
GENOMIC
library_selection
ChIP
library_construction_protocol
Chromatin IPs were conducted with an antibody directed against CTCF (Upstate, #07-729) comparable to ChIP experiments described in Woellmer et al (2012) (Woellmer A, Arteaga-Salas JM, Hammerschmidt W (2012) BZLF1 governs CpG-methylated chromatin of Epstein-Barr virus reversing epigenetic repression. PLoS Pathog 8:e1002902. doi: 10.1371/journal.ppat.1002902). DNA fragments were isolated in principle as described in Woellmer et al (2012) (Woellmer A, Arteaga-Salas JM, Hammerschmidt W (2012) BZLF1 governs CpG-methylated chromatin of Epstein-Barr virus reversing epigenetic repression. PLoS Pathog 8:e1002902. doi: 10.1371/journal.ppat.1002902). The library construction was performed by the company Vertis Biotechnology AG (Freising, Germany) using TrueSeq sequencing adaptors and DNA fragments of 300 to 500 nt in length.